The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2011Dopamine D1 Positive Modulators for the Treatment of Parkinson's Disease
Objective/Rationale:
L-DOPA is the standard treatment of Parkinson’s disease (PD) but prolonged use results in dyskinesia. D2 agonists often require L-DOPA supplementation and can cause side effects... -
Rapid Response Innovation Awards, 2007Virtual Reality to Reduce Fall Risk in Patients with Parkinson’s Disease
Objective/Rationale:
Virtual Reality (VR) allows for training in complex environments, while motivating subjects to perform numerous repetitions of the training tasks under well-controlled conditions... -
Fall 2021 RFP: Outcome Measures, 2022Development of Standardized Measurements for Monitoring the Progression of Parkinson’s Disease via MRI
Study Rationale: One of the difficulties in research towards new treatments in Parkinson’s disease (PD) is the diversity of disease presentations and the lack of tools to measure the effect of a...
-
Therapeutics Development Initiative, 2008Development of ERb agonists for the treatment of Parkinson's Disease
Objective/Rationale:
Estrogens modulate many cerebral functions such as mental state, mood, cognition and locomotion. Data indicate that estrogens may slow down the development and progression of PD... -
Rapid Response Innovation Awards, 2014Effect of Dietary Ketosis On Alpha-Synuclein Accumulation
Study Rationale:
A key feature of Parkinson’s disease is abnormal accumulation of the protein alpha-synuclein. Production of organic compounds called ketones is a normal metabolic process that occurs... -
MJFF Research Grant, 2011fMRI of First Degree Relatives of LRRK2 Positive PD Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in Parkinson’s disease (PD) patients who recently converted into a diseased...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.